Literature DB >> 3542948

Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies.

C S Easmon, J P Crane, A Blowers.   

Abstract

Ciprofloxacin is taken up rapidly by both human neutrophils and mouse peritoneal macrophages. It does not appear to be bound firmly within the cell and can be eluted readily if the extracellular concentration is lowered. Uptake does not depend on an active transport mechanism. Intracellular ciprofloxacin is biologically active reducing the survival of intracellular Staphylococcus aureus and Mycobacterium fortuitum, in vitro. In vivo, ciprofloxacin was effective in treating a murine systemic infection with an intracellular pathogen Salmonella typhimurium. The progress of infection in sensitive mice with no natural immunity was delayed by ciprofloxacin although at the dosage used the mice were not cured. These results suggested that clinical studies in patients infected by intracellular pathogens are warranted and that ciprofloxacin may have an important role in the treatment of this type of infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3542948     DOI: 10.1093/jac/18.supplement_d.43

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  37 in total

1.  Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever.

Authors:  M Hussein Gasem; Monique Keuter; Wil M V Dolmans; Johanna Van Der Ven-Jongekrijg; Robert Djokomoeljanto; Jos W M Van Der Meer
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Functional characterization of Brucella melitensis NorMI, an efflux pump belonging to the multidrug and toxic compound extrusion family.

Authors:  Martine Braibant; Laurence Guilloteau; Michel S Zygmunt
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

3.  Lack of effective bactericidal activity of new quinolones against Brucella spp.

Authors:  J A García-Rodriguez; J E García Sánchez; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 4.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 5.  Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.

Authors:  D E Nix; S D Goodwin; C A Peloquin; D L Rotella; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  In vitro and in vivo ciprofloxacin pharmacokinetics in human neutrophils.

Authors:  R Garraffo; D Jambou; R M Chichmanian; S Ravoire; P Lapalus
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 7.  Activity of antibiotics against microorganisms ingested by mononuclear phagocytes.

Authors:  P J van den Broek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

Review 8.  Quinolones in Salmonella typhi infection.

Authors:  H L DuPont
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Behavior of antibiotics during human necrotizing pancreatitis.

Authors:  C Bassi; P Pederzoli; S Vesentini; M Falconi; A Bonora; H Abbas; A Benini; E M Bertazzoni
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  In vitro activities of new macrolides and rifapentine against Brucella spp.

Authors:  J A García-Rodríguez; J L Muñoz Bellido; M J Fresnadillo; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.